www.avalotx.com Open in urlscan Pro
52.28.64.59  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About
   * Overview
   * Leadership Team
   * Board of Directors
   * Contact
 * Pipeline
   * Overview
   * AVTX-009
   * Under Strategic Review
 * Patients and Families
   * Overview
   * Patient Advocacy
   * Access to Investigational Therapies
 * Investors
   * Overview
   * News / Events
   * Company Information
   * Analyst Coverage
   * Stock Data
   * SEC Filings
   * Annual Report & Proxy
   * Corporate Governance
 * Resources
   * Access to Investigational Therapies
 * Careers


INNOVATION


DRIVEN BY COMPASSION


HOME


ABOUT US

Avalo Therapeutics is a clinical stage biotechnology company focused on the
treatment of immune dysregulation.


OUR PIPELINE

Avalo’s lead asset is AVTX-009,
an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two
additional product candidates which include quisovalimab (anti-LIGHT mAb) and
AVTX-008 (BTLA agonist fusion protein).


PRESENTATIONS


December 2024 Corporate Presentation

 


RECENT NEWS

Nov 12, 2024 7:00 am
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of
Private Placement Warrants
Nov 11, 2024 7:00 am
Avalo Therapeutics to Present at Upcoming Investor Conferences
View All News



INVESTOR RELATIONS

December 2024 Corporate Presentation View 10-K View Investor Relations
© 2024 Avalo Therapeutics, Inc.
Contact Privacy Policy Disclaimer Sitemap